English	French	Notes	Complete/Exclude
      CISPLATIN..........: NA        INTERFERON.........: NA			
      BCNU...............: NA        CYTARABINE (ARA-C).: NA			
      BCNU WAFER IMPLANT.: NA        OTHER..............: NA			
1383      BCNU WAFER IMPLANT...........			
 81. OTHER TYPE OF SUBSEQUENT TX                                                      FOR RECURRENCE/PROGRESSION...: None			
1393 81. OTHER TYPE OF SUBSEQUENT TX                                                      FOR RECURRENCE/PROGRESSION...			
82. DATE OF LAST CONTACT OR DEATH			
83. VITAL STATUS			
84. CANCER STATUS			
 STATUS AT LAST CONTACT			
 82. DATE OF LAST CONTACT OR DEATH..: 			
15 83. VITAL STATUS...................			
 84. CANCER STATUS..................: 			
 1. FACILITY ID NUMBER (FIN)......: 			
 2. ACCESSION NUMBER..............: 			
 3. SEQUENCE NUMBER...............: 			
 4. POSTAL CODE AT DIAGNOSIS......: 			
 5. DATE OF BIRTH.................: 			
 7. SPANISH ORIGIN................: 			
10. PRIOR EXPOSURE TO RADIATION...: 			
11. PRIMARY PAYER AT DIAGNOSIS....: 			
12. PRIOR MEDICAL CONDITIONS:			
     MULTIPLE SCLEROSIS (MS)......: 			
     MYOCARDIAL INFARCTION (MI)...: 			
     CEREBROVASCULAR DISEASE......: 			
     MALIGNANT MELANOMA...........: 			
     OTHER SKIN CANCER............: 			
     COLON OR OTHER GI CANCERS....: 			
14. GENETIC PREDISPOSITION:			
     VON HIPPEL-LINDAU DISEASE....: 			
     TUBEROUS SCLEROSIS...........: 			
     TURCOT SYNDROME..............: 			
     LI-FRAUMENI SYNDROME.........: 			
     KOWDEN DISEASE...............: 			
     NEVOID BASAL CELL CARCINOMA			
 15. USUAL OCCUPATION.............: 			
 16. USUAL INDUSTRY...............: 			
17. CLASS OF CASE.................: 			
     CHANGE IN SENSE OF SMELL AND/			
      OR TASTE....................: 			
     ALTERED ALERTNESS............: 			
     SPEECH DISTURBANCE...........: 			
     PERSONALITY CHANGES..........: 			
     MEMORY LOSS..................: 			
     LACK OF CONCENTRATION........: 			
     DOUBLE VISION................: 			
     OTHER VISUAL DISTURBANCE.....: 			
     DECREASED HEARING............: 			
     WEAKNESS OR PARALYSIS........: 			
     DIFFICULTY IN COORDINATION/			
     GENERALIZED SEIZURE..........: 			
     FOCAL SEIZURE................: 			
     BLADDER INCONTINENCE.........: 			
     BOWEL INCONTINENCE...........: 			
     PAIN (OTHER THAN HEADACHE)...: 			
     WEIGHT CHANGE................: 			
Print Intracranial & CNS PCE			
19. NEUROLOGICAL FINDINGS:			
     MEMORY OR JUDGEMENT..........: 			
     VISUAL ACUITY................: 			
     VISUAL FIELDS................: 			
     EYE MOVEMENTS (EOM)..........: 			
     FACIAL SENSATION.............: 			
     FACIAL MOVEMENT..............: 			
     GAG REFLEX...................: 			
      SHRUG STRENGTH..............: 			
     ARTICULATION OR ENUNCIATION..: 			
     TONGUE FASCICULATIONS OR			
     DECREASE IN SENSATION OF ANY			
     CORTICAL SENSORY DEFICIT.....: 			
     WEAKNESS, ATROPHY OR			
      FASCICULATION OF ANY SITE...: 			
     ATAXIA OF GAIT...............: 			
     TRUNCAL ATAXIA...............: 			
     RAPID ALTERNATING MOVEMENTS..: 			
     FINGER TO FINGER NOSE TESTING: 			
     HEEL TO KNEE TO SHIN TESTING.: 			
     DEEP TENDON REFLEXES IN UPPER			
     DEEP TENDON REFLEXES IN LOWER			
     BABINSKI SIGN................: 			
     HOFFMAN REFLEX...............: 			
     OTHER ABNORMAL REFLEXES......: 			
20. PRE-THERAPY DIAGNOSTIC STUDIES:			
     CT SCAN OF BRAIN.............: 			
     CT SCAN OF SPINE.............: 			
     ISOTOPE BRAIN SCAN...........: 			
     SPECT SCAN...................: 			
     MRI OF BRAIN.................: 			
     MRI OF SPINE.................: 			
     FUNCTIONAL MRI...............: 			
21. TUMOR LOCATION/INVOLVEMENT:			
     FRONTAL LOBE.................: 			
     TEMPORAL LOBE................: 			
     PARIETAL LOBE................: 			
     OCCIPITAL LOBE...............: 			
     OPTIC NERVES.................: 			
     PITUITARY GLAND..............: 			
     PINEAL GLAND.................: 			
     BRAIN STEM...................: 			
     SKULL BASE...................: 			
     OTHER SKULL..................: 			
     SPINAL CORD..................: 			
     CEREBRAL SPINAL FLUID........: 			
     CRANIAL MENINGES.............: 			
     SPINAL MENINGES..............: 			
23. NUMBER OF TUMORS..............: 			
24. DATE OF FIRST SYMPTOMS........: 			
25. DATE OF INITIAL DIAGNOSIS.....: 			
26. DATE OF PATHOLOGIC DIAGNOSIS..: 			
27. PRIMARY SITE (ICD-O-2)........: 			
28. WHO HISTOLOGICAL CLASSIFI-    			
     CATION OF TUMOR..............: 			
29. BEHAVIOR CODE (ICD-O-2).......: 			
31. DIAGNOSTIC CONFIRMATION.......: 			
32. MOLECULAR MARKERS.............: 			
33. TUMOR SIZE....................: 			
34. TUMOR SIZE (SOURCE)...........: 			
35. KARNOFSKY'S RATING PRIOR TO TX: 			
36. PROTOCOL PARTICIPATION........: 			
37. PROTOCOL PHASE................: 			
38. DATE OF FIRST COURSE TREATMENT: 			
39. DATE OF INPATIENT ADMISSION...: 			
40. DATE OF INPATIENT DISCHARGE...: 			
41. DATE OF NON CANCER-DIRECTED			
     NONE, NO NON CA-DIRECTED			
      SURGICAL PROCEDURE..........: 			
     VENTRICULOSTOMY, OR EXTERNAL			
      VENTRICULAR DRAIN...........: 			
     CSF SHUNT,			
      THIRD VENTRICULOSTOMY.......: 			
     STEREOTACTIC BIOPSY..........: 			
     OPEN BRAIN BIOPSY............: 			
     OPEN BIOPSY OF SPINAL CORD			
     LAMINECTOMY FOR SPINAL CORD			
      TUMOR, W/O TUMOR RESECTION,			
       W/O OPENING DURA...........: 			
       W OPENING DURA.............: 			
     UNKNOWN IF SURGERY DONE......: 			
43. DATE OF CA-DIRECTED SURGERY...: 			
44. SURGICAL APPROACH.............: 			
45. EXTENT OF SURGICAL RESECTION..: 			
46. SIZE OF RESIDUAL PRIMARY TUMOR			
     AFTER CA-DIR SURGERY.........: 			
47. SIZE OF RESIDUAL PRIMARY TUMOR			
     AFTER CA-DIR SURGERY (SOURCE): 			
     ANESTHETIC PROBLEM...........: 			
     HEMORRHAGE AT OPERATIVE SITE.: 			
     DVT (DEEP VENOUS THROMBOSIS).: 			
     PERSISTENT NEUROLOGICAL			
      WORSENING > 4 DAYS POST-OP..: 			
49. REASON FOR NO SURGERY.........: 			
50. RADIATION THERAPY.............: 			
51. DATE RADIATION STARTED........: 			
52. DATE RADIATION ENDED..........: 			
53. TOTAL RADIATION DOSE (cGy)....: 			
54. NUMBER OF TREATMENTS TO THIS			
55. TYPE OF EXT BEAM RADIATION....: 			
56. INTERSTITIAL RAD/BRACHYTHERAPY: 			
57. STEREOTACTIC RADIOSURGERY.....: 			
58. RADIATION/SURGERY SEQUENCE....: 			
59. RADIATION COMPLICATIONS:			
     SKIN REACTIONS...............: 			
     NAUSEA OR VOMITING...........: 			
     NEUROLOGIC WORSENING.........: 			
60. REASON FOR NO RADIATION.......: 			
61. DATE CHEMOTHERAPY STARTED.....: 			
     BCNU, WAFER IMPLANT..........: 			
64. CHEMOTHERAPEUTIC ROUTE........: 			
65. CHEMOTHERAPY COMPLICATIONS:			
     HEARING LOSS.................: 			
     NAUSEA AND VOMITING REQUIRING			
      CESSATION OF CHEMOTHERAPY...: 			
     PERIPHERAL BLOOD COUNT DROP/			
      /BLEEDING/CESSATION OF CHEMO			
      AND/OR TRANSFUSION..........: 			
     PERIPHERAL NEUROPATHY........: 			
     RENAL FAILURE................: 			
     PULMONARY TOXICITY...........: 			
66. REASON FOR NO CHEMOTHERAPY....: 			
67. DATE OTHER TREATMENT STARTED..: 			
68. OTHER TREATMENT...............: 			
69. KARNOFSKY'S RATING AT TIME OF			
RECURRENCE/PROGRESSION			
70. DATE OF FIRST RECURRENCE......: 			
71. TYPE OF FIRST RECURRENCE......: 			
72. DATE OF PROGRESSION...........: 			
73. TYPE OF PROGRESSION...........: 			
75. KARNOFSKY'S RATING AT TIME OF			
SUBSEQUENT TREATMENT			
76. DATE OF SUBSEQUENT TREATMENT			
     FOR RECURRENCE/PROGRESSION...: 			
77. PROTOCOL PARTCIPATION			
     (SUBSEQUENT TREATMENT).......: 			
78. TYPE OF SUBSEQUENT SURGICAL TX			
79. TYPE OF SUBSEQUENT RADIATION			
     TX FOR RECURRENCE/PROGRESSION: 			
81. OTHER TYPE OF SUBSEQUENT TX			
STATUS AT LAST CONTACT			
82. DATE OF LAST CONTACT OR DEATH.: 			
83. VITAL STATUS..................: 			
84. CANCER STATUS.................: 			
2001 Patient Care Evaluation Study of Non-Small Cell Lung Carcinoma			
1400      CO-MORBID CONDITION #1.......			
1400.1      CO-MORBID CONDITION #2.......			
1400.2      CO-MORBID CONDITION #3.......			
1400.3      CO-MORBID CONDITION #4.......			
1400.4      CO-MORBID CONDITION #5.......			
1400.5      CO-MORBID CONDITION #6.......			
1401  2. DURATION OF TOBACCO USE.......			
1403  3. PERSONAL HISTORY OF OTHER                                                        INVASIVE MALIGNANCIES PRIOR                                                      TO THIS CANCER DIAGNOSIS....//^S X=PHDEF			
This item describes the patient's prior history of other invasive			
malignancies.  If the patient has a history of other malignancies			
report the ICD-O-3 site code for the most recently diagnosed disease.			
If the patient has no personal history of other cancer, code C88.8. If			
the patient's personal history of other invasive malignancies is not			
Allowable Codes: C00.0 thru C80.9 - valid ICD-0-3 site (topography) codes			
                 C88.8 - no personal history of other cancer			
                 C99.9 - personal history of other cancer not documented			
This patient has no other primaries.			
Other primaries for this patient:			
Date DX			
 TUMOR IDENTIFICATION AND DIAGNOSIS			
  4. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:			
1404.1      SHORTNESS OF BREATH..........			
1404.2      WEIGHT LOSS..................			
1404.4      PALPABLE LYMPH NODES.........			
  5. SCREENING FOR HIGH RISK/ASYMPTOMATIC PRESENTATION:			
1405.1      CT SCAN......................			
  6. INITIAL DIAGNOSTIC STUDIES (PRE-THERAPY):			
1406      HISTORY AND PHYSICAL.........			
1406.4      THOROCOTOMY/OPEN BIOPSY......			
 TUMOR EVALUATION			
  7. PULMONARY FUNCTION TESTS:			
1407      FVC (forced vital capacity)..			
1407.1      FEV (forced expiratory vol)..			
1408  8. LIVER FUNCTION TESTS..........			
  9. RADIOLOGIC EVALUATION:			
     BONE SCAN:			
1409      BONE SCAN....................			
1409.2       VASCULAR INVASION...........			
1409.3       MEDIASTINAL LYMPH NODES.....			
1409.4       SIZE OF DOMINANT TUMOR (mm).			
1409.5       NUMBER OF TUMORS............			
1409.6       EVIDENCE OF METASTASIS......			
     CT SCAN OF CHEST:			
1410      CT SCAN OF CHEST.............			
1410.2       VASCULAR INVASION...........			
1410.3       MEDIASTINAL LYMPH NODES.....			
1410.4       SIZE OF DOMINANT TUMOR (mm).			
1410.5       NUMBER OF TUMORS............			
1410.6       EVIDENCE OF METASTASIS......			
     CT SCAN OF BRAIN:			
1411      CT SCAN OF BRAIN.............			
1411.2       VASCULAR INVASION...........			
1411.3       MEDIASTINAL LYMPH NODES.....			
1411.4       SIZE OF DOMINANT TUMOR (mm).			
1411.5       NUMBER OF TUMORS............			
1411.6       EVIDENCE OF METASTASIS......			
     MRI SCAN OF CHEST:			
1412      MRI SCAN OF CHEST............			
1412.2       VASCULAR INVASION...........			
1412.3       MEDIASTINAL LYMPH NODES.....			
1412.4       SIZE OF DOMINANT TUMOR (mm).			
1412.5       NUMBER OF TUMORS............			
1412.6       EVIDENCE OF METASTASIS......			
     MRI SCAN OF BRAIN:			
1413      MRI SCAN OF BRAIN............			
1413.2       VASCULAR INVASION...........			
1413.3       MEDIASTINAL LYMPH NODES.....			
1413.4       SIZE OF DOMINANT TUMOR (mm).			
1413.5       NUMBER OF TUMORS............			
1413.6       EVIDENCE OF METASTASIS......			
     PET SCAN:			
1414      PET SCAN.....................			
1414.2       VASCULAR INVASION...........			
1414.3       MEDIASTINAL LYMPH NODES.....			
1414.4       SIZE OF DOMINANT TUMOR (mm).			
1414.5       NUMBER OF TUMORS............			
1414.6       EVIDENCE OF METASTASIS......			
     X-RAY OF CHEST:			
1415      X-RAY OF CHEST...............			
1415.2       VASCULAR INVASION...........			
1415.3       MEDIASTINAL LYMPH NODES.....			
1415.4       SIZE OF DOMINANT TUMOR (mm).			
1415.5       NUMBER OF TUMORS............			
1415.6       EVIDENCE OF METASTASIS......			
 10. PRE-OP LYMPH NODE MAPPING:			
1416      HIGHEST MEDIASTINAL (level 1)			
1416.1      UPPER PARATRACHEAL (level 2).			
1416.2      PREVASCULAR AND RETROTRACHEAL                                                    (level 3)...................			
1416.3      LOWER PARATRACHEAL (level 4).			
1416.8      PULMONARY LIGAMENT (level 9).			
       EMPHYSEMA...................: NA, test not performed			
       VASCULAR INVASION...........: NA, test not performed			
       MEDIASTINAL LYMPH NODES.....: NA, test not performed			
       SIZE OF DOMINANT TUMOR (mm).: Test not performed			
       NUMBER OF TUMORS............: Test not performed			
       EVIDENCE OF METASTASIS......: NA, test not performed			
       EMPHYSEMA...................: Not documented			
       VASCULAR INVASION...........: Not documented			
       MEDIASTINAL LYMPH NODES.....: Not documented			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
